There is not going to be much news in the near term until readout in January for MSA blinded trial. In my opinion MSA is not a widespread issue and this is why it does not get much publicity. We should now start focusing on Parkinson’s which is much more widely known. I am sure that the learning through MSA trials can be translated into some sort of plan to move Parkinson’s treatment forward. An announcement around that will help share price significantly in my opinion. We need to give something to the Michael J Fox Foundation to reinvest in and move Parkinson’s trial forward. We are a bit flat footed and need to start running.
Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial, page-118
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(14.3%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $381 | 109K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 42 | 60011843 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 125715587 | 24 |
View Market Depth
| Last trade - 14.28pm 23/08/2024 (20 minute delay) ? |
| ATH (ASX) Chart |